drugset / Trial / NCT00744679
A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State
Non-randomizedSingle-groupOpen-labelBasic science
Summary
The primary objective is to assess the pharmacokinetic (PK) profile of natalizumab (Tysabri) at steady state. The secondary objective is to assess the pharmacodynamics (PD) profile (α4 integrin saturation) of Tysabri at steady state.
Timeline
- Start
- 2008-11
- Primary completion
- 2008-12
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | natalizumab | Monoclonal antibody | 300 mg | — |